A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Status:
Active, not recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free
light chains that cannot be broken down. These free light chains bind together to form
amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys,
heart, liver, spleen, nervous system and digestive tract.
The primary purpose of this study is to determine the recommended dose of CAEL-101 to
facilitate progression of further clinical trials and evaluate safety and tolerability of
CAEL-101 in combination with the standard of care (SoC)
cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab .